Dr. Christopher Dvorak, MD

NPI: 1861527657
Total Payments
$125,679
2024 Payments
$2,840
Companies
11
Transactions
98

Payment Breakdown by Category

Consulting$91,064 (72.5%)
Travel$22,580 (18.0%)
Other$8,850 (7.0%)
Food & Beverage$2,311 (1.8%)
Research$875.00 (0.7%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $91,064 37 72.5%
Travel and Lodging $22,580 28 18.0%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,300 1 5.0%
Honoraria $2,550 3 2.0%
Food and Beverage $2,311 27 1.8%
Unspecified $875.00 2 0.7%

Payments by Type

General
$124,804
96 transactions
Research
$875.00
2 transactions

Top Paying Companies

Company Total Records Latest Year
Alexion Pharmaceuticals, Inc. $60,522 57 $0 (2024)
Amgen Inc. $33,677 9 $0 (2022)
JAZZ PHARMACEUTICALS INC. $15,284 17 $0 (2022)
Omeros Corporation $6,250 3 $0 (2021)
Chiesi USA, Inc. $4,055 3 $0 (2023)
Novartis Pharmaceuticals Corporation $2,486 3 $0 (2020)
Medexus Pharma, Inc. $2,040 1 $0 (2024)
Leadiant Biosciences, Inc. $875.00 2 $0 (2020)
Apellis Pharmaceuticals, Inc. $250.00 1 $0 (2022)
VERTEX PHARMACEUTICALS INCORPORATED $220.83 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2024 $2,840 3 Medexus Pharma, Inc. ($2,040)
2023 $17,404 13 Alexion Pharmaceuticals, Inc. ($16,809)
2022 $17,353 7 Amgen Inc. ($16,277)
2021 $28,315 12 Amgen Inc. ($15,200)
2020 $7,199 7 Omeros Corporation ($3,850)
2019 $32,884 26 Alexion Pharmaceuticals, Inc. ($29,157)
2018 $6,852 11 Alexion Pharmaceuticals, Inc. ($4,204)
2017 $12,831 19 Jazz Pharmaceuticals Inc. ($6,148)

All Payment Transactions

98 individual payment records from CMS Open Payments — Page 1 of 4

Date Company Product Nature Form Amount Type
07/13/2024 Medexus Pharma, Inc. Consulting Fee Cash or cash equivalent $2,040.00 General
05/20/2024 Alexion Pharmaceuticals, Inc. ULTOMIRIS (Biological) Consulting Fee Cash or cash equivalent $780.00 General
Category: Rare Disease
01/09/2024 ADMA BioManufacturing LLC Consulting Fee Cash or cash equivalent $20.32 General
07/20/2023 Chiesi USA, Inc. REVCOVI (Drug) Consulting Fee Cash or cash equivalent $595.00 General
Category: ERT FOR ADA-SCID
05/10/2023 Alexion Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $7,700.00 General
04/24/2023 Alexion Pharmaceuticals, Inc. Travel and Lodging Cash or cash equivalent $709.43 General
04/24/2023 Alexion Pharmaceuticals, Inc. Food and Beverage Cash or cash equivalent $59.41 General
04/24/2023 Alexion Pharmaceuticals, Inc. Travel and Lodging Cash or cash equivalent $50.20 General
04/23/2023 Alexion Pharmaceuticals, Inc. Travel and Lodging Cash or cash equivalent $9.28 General
04/22/2023 Alexion Pharmaceuticals, Inc. Travel and Lodging Cash or cash equivalent $21.89 General
04/20/2023 Alexion Pharmaceuticals, Inc. Travel and Lodging In-kind items and services $3,868.95 General
04/20/2023 Alexion Pharmaceuticals, Inc. Travel and Lodging In-kind items and services $170.90 General
02/14/2023 Alexion Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $3,900.00 General
02/14/2023 Alexion Pharmaceuticals, Inc. Food and Beverage In-kind items and services $116.72 General
02/14/2023 Alexion Pharmaceuticals, Inc. Travel and Lodging In-kind items and services $111.23 General
02/14/2023 Alexion Pharmaceuticals, Inc. Food and Beverage In-kind items and services $91.48 General
09/29/2022 Chiesi USA, Inc. Consulting Fee Cash or cash equivalent $759.50 General
08/31/2022 Apellis Pharmaceuticals, Inc. Empaveli (Drug) Consulting Fee Cash or cash equivalent $250.00 General
Category: Hematology
04/24/2022 JAZZ PHARMACEUTICALS INC. DEFITELIO (Drug) Food and Beverage In-kind items and services $66.55 General
Category: HEMATOLOGY/ONCOLOGY
03/07/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $4,600.00 General
02/22/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $5,400.00 General
01/18/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $6,200.00 General
01/18/2022 Amgen Inc. Consulting Fee Cash or cash equivalent $76.67 General
11/22/2021 Alexion Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $550.00 General
09/27/2021 Amgen Inc. Consulting Fee Cash or cash equivalent $6,400.00 General

Research Studies & Clinical Trials

Study Name Company Amount Records
Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (elpegademase-lvlr) Treatment in ADA-SCID Subjects Requiring Enzyme Replacement Therapy Leadiant Biosciences, Inc. $875.00 2

About Dr. Christopher Dvorak, MD

Dr. Christopher Dvorak, MD is a Pediatric Hematology-Oncology healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1861527657.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Dvorak, MD has received a total of $125,679 in payments from pharmaceutical and medical device companies, with $2,840 received in 2024. These payments were reported across 98 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($91,064).

Practice Information

  • Specialty Pediatric Hematology-Oncology
  • Location Palo Alto, CA
  • Active Since 02/22/2007
  • Last Updated 03/24/2008
  • Taxonomy Code 2080P0207X
  • Entity Type Individual
  • NPI Number 1861527657

Products in Payments

  • SOLIRIS (Drug) $37,683
  • Defitelio (Drug) $8,796
  • DEFITELIO (Drug) $6,488
  • Narsoplimab (Drug) $3,850
  • FERRIPROX (Drug) $2,700
  • Revcovi (Biological) $875.00
  • ULTOMIRIS (Biological) $780.00
  • REVCOVI (Drug) $595.00
  • Empaveli (Drug) $250.00
  • Soliris (Drug) $150.00
  • Ultomiris (Drug) $150.00
  • KYMRIAH (Biological) $124.12

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Hematology-Oncology Doctors in Palo Alto